Novo Nordisk is considering using a priority review voucher for the candidate, a company spokesman confirmed by email. Doing so would expedite semaglutide’s trip down the regulatory pathway—and hasten a head-to-head battle in the diabetes sphere with dru https://www.fiercepharma.com/marketing/novo-nordisk-s-semaglutide-headed-toward-a-lilly-showdown-will-novo-speed-it-up

A new complications-centric model identifies four distinct, evidence-based disease stages along the type 2 diabetes spectrum, emphasizing preventive care that begins at the first signs of insulin resistance, according to a joint position statement from t https://www.healio.com/endocrinology/diabetes/news/in-the-journals/%7B13ecdfad-cd86-441c-bccf-d571f2cbd209%7D/position-statement-identifies-4-distinct-stages-of-type-2-diabetes

Medicaid and state employee health insurance programs are improving their coverage for adult obesity, but a treatment gap still exists, according to findings published in Obesity. The gap refers to a growing acceptance of treatments to address mild and s https://www.healio.com/endocrinology/obesity/news/in-the-journals/%7B0a9f765f-1f88-44d4-b392-35b6a1ac529c%7D/obesity-treatment-in-state-insurance-plans-improving-gap-still-exists

The FDA placed a clinical hold on an investigational new drug application for a second-generation MetAP2 inhibitor in development for the treatment of type 2 diabetes, citing cardiovascular safety concerns, Zafgen announced in a press release. The FDA ci https://www.healio.com/endocrinology/diabetes/news/online/%7B81e950dc-8709-4789-9527-298ffc137c9d%7D/fda-suspends-clinical-trial-for-investigational-diabetes-drug

In this study, researchers assessed the connection between food insecurity and prediabetes, and also identified specific subgroups for early clinical intervention via analyzing cross-sectional data from 25,814 participants from the National Health and Nu https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(18)31088-X/fulltext?rss=yes